clinical trial · NCT06789848
Ligufalimab and Cadonilimab in Advanced Liver Cancers
University of Texas Southwestern Medical Center·phase2·recruiting·n = 64
Advanced Hepatocellular CarcinomaRefractory Hepatocellular CarcinomaBiliary Tract CancerLigufalimabCadonilimab
brief summary
The goal of this clinical trial is to find out if the combination of Ligufalimab and Cadonilimab are effective in treating advanced hepatobiliary cancers that have failed prior therapy.
started
Feb 18, 2025
primary completion
May 31, 2029
completion
May 31, 2030
last updated
Feb 27, 2026
detailed description
The study is an open-label, non-randomized, phase II basket therapeutic clinical trial. To determine the objective response rate of combination ligufalimab and cadonilimab in refractory and advanced hepatocellular carcinoma and biliary tract cancers.
official title
Phase II Basket Trial of Ligufalimab (AK117) and Cadonilimab (AK104) in Advanced Hepatobiliary Cancers
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol